These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37741447)

  • 1. Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.
    Li X; Suh HS; Lachaine J; Schuh AC; Pratz K; Betts KA; Song J; Dua A; Bui CN
    Value Health; 2023 Dec; 26(12):1689-1696. PubMed ID: 37741447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
    He H; Wen X; Zheng H
    Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
    Choi M; Song J; Bui CN; Ma E; Chai X; Yin L; Betts KA; Kapustyan T; Montez M; LeBlanc TW
    J Manag Care Spec Pharm; 2022 Sep; 28(9):980-988. PubMed ID: 35708343
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.
    Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T
    Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
    Wang L; Song J; Xiao X; Li D; Liu T; He X
    J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.
    Pratz KW; Panayiotidis P; Recher C; Wei X; Jonas BA; Montesinos P; Ivanov V; Schuh AC; DiNardo CD; Novak J; Pejsa V; Stevens D; Yeh SP; Kim I; Turgut M; Fracchiolla N; Yamamoto K; Ofran Y; Wei AH; Bui CN; Benjamin K; Kamalakar R; Potluri J; Mendes W; Devine J; Fiedler W
    Blood Cancer J; 2022 Apr; 12(4):71. PubMed ID: 35443742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].
    Hu Y; Jin J; Zhang Y; Hu JD; Li JM; Wei XD; Gao SJ; Zha JH; Jiang Q; Wu J; Mendes W; Wei AH; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2021 Apr; 42(4):288-294. PubMed ID: 33979972
    [No Abstract]   [Full Text] [Related]  

  • 8. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
    Wei AH; Montesinos P; Ivanov V; DiNardo CD; Novak J; Laribi K; Kim I; Stevens DA; Fiedler W; Pagoni M; Samoilova O; Hu Y; Anagnostopoulos A; Bergeron J; Hou JZ; Murthy V; Yamauchi T; McDonald A; Chyla B; Gopalakrishnan S; Jiang Q; Mendes W; Hayslip J; Panayiotidis P
    Blood; 2020 Jun; 135(24):2137-2145. PubMed ID: 32219442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 10. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 11. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
    Qin Y; Kuang P; Liu T
    Clin Exp Med; 2023 Jun; 23(2):219-227. PubMed ID: 35066728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study.
    Pasvolsky O; Shimony S; Ram R; Shimoni A; Shargian L; Avni B; Wolach O; Shochat T; Yerushalmi R; Amit O; Raanani P; Yeshurun M
    Ann Hematol; 2022 Feb; 101(2):379-387. PubMed ID: 34628534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
    Sutter T; Schittenhelm M; Volken T; Lehmann T
    Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
    Agarwal S; Gopalakrishnan S; Mensing S; Potluri J; Hayslip J; Kirschbrown W; Friedel A; Menon R; Salem AH
    Hematol Oncol; 2019 Oct; 37(4):464-473. PubMed ID: 31251400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
    Dillon R; Maycock S; Jackson A; Fox S; Freeman S; Craddock C; Thomas C; Homer E; Leahy J; Mamwell A; Potter N; Russell N; Wei A; Ommen HB; Hemmaway C; Knapper S; Billingham L
    BMC Cancer; 2022 Nov; 22(1):1174. PubMed ID: 36376888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons.
    Tremblay G; Westley T; Cappelleri JC; Arondekar B; Chan G; Bell TJ; Briggs A
    Clinicoecon Outcomes Res; 2019; 11():551-565. PubMed ID: 31564931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
    Yoshida C; Kondo T; Ito T; Kizaki M; Yamamoto K; Miyamoto T; Morita Y; Eto T; Katsuoka Y; Takezako N; Uoshima N; Imada K; Ando J; Komeno T; Mori A; Ishikawa Y; Satake A; Watanabe J; Kawakami Y; Morita T; Taneike I; Nakayama M; Duan Y; Garbayo Guijarro B; Delgado A; Llamas C; Kiyoi H
    Int J Hematol; 2022 Jul; 116(1):89-101. PubMed ID: 35394258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
    Petit C; Saillard C; Mohty B; Hicheri Y; Villetard F; Maisano V; Charbonnier A; Rey J; D'Incan E; Rouzaud C; Gelsi-Boyer V; Murati A; Lhoumeau AC; Ittel A; Mozziconacci MJ; Alary AS; Hospital MA; Vey N; Garciaz S
    Eur J Haematol; 2024 Apr; 112(4):530-537. PubMed ID: 38031389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
    J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
    Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
    Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.